Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinglisan (also known as Qinglisan granules or 清利散) is a traditional Chinese medicine (TCM) formula developed by Beijing Children's Hospital, Capital Medical University. It is formulated as oral granules and is composed of six herbal and mineral ingredients: Cercis chinensis bark (紫荆皮), Forsythia suspensa fruit (连翘), Akebia trifoliata var. australis stem (白木通), Talcum (滑石), Plantago asiatica seed (车前子), and Glycyrrhiza uralensis root (甘草). Qinglisan is primarily used in combination with Jietongyin lotion (洁童阴洗液) as an alternative to oral antibiotics (such as amoxicillin) for the treatment of pediatric bacterial vulvovaginitis in girls. The formula works by clearing heat, resolving dampness, promoting diuresis, and relieving toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qinglisan.